Shots:
- GSK has entered into a strategic research collaboration with LTZ Therapeutics to advance the development of novel myeloid cell engagers (MCEs) in oncology, leveraging LTZ’s immune-engager platform
- Under the collaboration, GSK & LTZ aim to develop up to four MCE therapies for hematologic cancers & solid tumors, with GSK receiving an exclusive option to license global development & commercial rights for these pre-clinical therapies
- As per the terms, LTZ will receive a $50M upfront payment, plus preclinical, clinical, regulatory, & commercial milestones, along with tiered royalties on global net sales of any products developed through the collaboration
Ref: GSK | Image: GSK and LTZ Therapeutics | Press Release
Related News:- Merus Partners with Halozyme to Develop Subcutaneous Petosemtamab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
